William Grossman

This profile gathers the share dealings of William Grossman across 3 companies, led by Arcus Biosciences, Inc., Bellicum Pharmaceuticals, Inc and enGene Therapeutics Inc. We count 16 filings; the first trade dates from 5 February 2018 and the latest from 22 September 2026.

On the open market, the record shows 5 purchases worth €15k and 6 sales worth €366k. On balance, insiders were net sellers of €351k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 5 share grants. In 2026 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €1,665. None of the 5 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The newest entry dates from 24 September 2026: an open-market purchase of €8,763, in enGene Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.